Article

PDF
Access to the PDF text
Advertising



Archives of cardiovascular diseases
Volume 110, n° 5
pages 303-316 (mai 2017)
Doi : 10.1016/j.acvd.2017.01.006
Received : 27 November 2016 ;  accepted : 17 January 2017
Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study
Devenir des adultes avec syndrome d’Eisenmenger traités par médicaments spécifiques anti-hypertenseur pulmonaire : données d’une étude multicentrique française
 

Figure 1




Figure 1 : 

Distribution of diagnoses in the study patients. The numbers at the top of the bars are the numbers of patients with the relevant diagnosis. ASD: atrial septal defect; CAT: common arterial trunk; cAVSD: complete atrioventricular septal defect; ccTGA: congenitally corrected transposition of the great arteries; DORV: double outlet right ventricle; pAPVR: partial anomalous pulmonary venous return; PDA: patient ductus arteriosus; TGA: transposition of the great arteries; TOF: tetralogy of Fallot; UV: univentricular heart; VSD: ventricular septal defect.


Figure 2




Figure 2 : 

Kaplan–Meier curves showing survival without major clinical events (death or transplantation) according to age at follow-up, overall and in subgroups defined by defect location, presence or absence of genetic syndrome and pulmonary arterial hypertension-specific drug therapy (PAH-SDT). A, B and C. Event-free survival. D. Event-free survival in patients with post-tricuspid (post-tric.) or combined defects. PAH<40 yo: pulmonary arterial hypertension diagnosis before 40 years of age; pre-tric.: pre-tricuspid.


Figure 3




Figure 3 : 

Kaplan–Meier curves showing survival without major clinical events (death or transplantation) according to time since the diagnosis of pulmonary artery hypertension, overall and in subgroups defined by defect location, pulmonary arterial hypertension-specific drug therapy (PAH-SDT) and functional class. A, B and D. Event-free survival. C. Event-free survival in patients with post-tricuspid (post-tric.) or combined defects. PAH<40 yo: pulmonary arterial hypertension diagnosis before 40 years of age; pre-tric.: pre-tricuspid; NYHA/WHO FC, New York Heart Association/World Health Organization functional class.

EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline